Efficacy and Safety Study of Oral Solithromycin (CEM-101) Compared to Oral Moxifloxacin in Treatment of Patients With Community-Acquired Bacterial Pneumonia

ClinicalTrials.gov ID: NCT01756339

Public ClinicalTrials.gov record NCT01756339. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

View official ClinicalTrials.gov record → Back to search

ClinicalTrials.gov public records Last synced Sep 3, 2026, 12:51 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Randomized, Double-Blind, Multi-Center Study to Evaluate the Efficacy and Safety of Oral Solithromycin (CEM-101) Compared to Oral Moxifloxacin in the Treatment of Adult Patients With Community-Acquired Bacterial Pneumonia

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

This study will evaluate the safety and efficacy of an experimental antibiotic, solithromycin, in the treatment of adult patients with community-acquired pneumonia.

Study identification

NCT ID: NCT01756339
Recruitment status: Completed
Study type: Interventional
Phase: Phase 3
Lead sponsor: Melinta Therapeutics, Inc.; Industry
Enrollment: 860 participants

Conditions and interventions

Conditions

Community-acquired Bacterial Pneumonia

Interventions

Drug · Other

Eligibility (public fields only)

Age range: 18 Years and older
Sex: All
Healthy volunteers: Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date: Nov 30, 2012
Primary completion: Sep 30, 2014
Completion: Sep 30, 2014
Last update posted: Mar 2, 2017

2012 – 2014

United States locations

U.S. sites: 25
U.S. states: 10
U.S. cities: 21

Facility	City	State	ZIP	Site status
Not listed	Glendale	California	91206	—
Not listed	Los Angeles	California	90015	—
Not listed	Mission Hills	California	91345	—
Not listed	Oxnard	California	93030	—
Not listed	Pasadena	California	91105	—
Not listed	Sylmar	California	91342	—
Not listed	Torrance	California	90502	—
Not listed	DeBary	Florida	32713	—
Not listed	DeLand	Florida	32720	—
Not listed	Miami	Florida	33126	—
Not listed	Miami	Florida	33144	—
Not listed	Saint Cloud	Florida	34769	—
Not listed	Tampa	Florida	33606	—
Not listed	Duluth	Georgia	30096	—
Not listed	New Bedford	Massachusetts	02740	—
Not listed	Butte	Montana	59701	—
Not listed	Columbus	Ohio	43035	—
Not listed	Downingtown	Pennsylvania	19335	—
Not listed	Summerville	South Carolina	29485	—
Not listed	Rapid City	South Dakota	57702	—
Not listed	Houston	Texas	77011	—
Not listed	Houston	Texas	77030	—
Not listed	Houston	Texas	77070	—
Not listed	Houston	Texas	77093	—
Not listed	Splendora	Texas	77372	—

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 94 non-U.S. sites.

About this trial record page

What this page shows: Public field values for ClinicalTrials.gov record NCT01756339, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from: Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh: Last update posted Mar 2, 2017 · Synced Sep 3, 2026

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT01756339 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →